**Table S3: Comparisons of Chemo-ADPT between groups using eribulin as second line and late lines after excluding those with eribulin as the first line chemotherapy treatment**

|  |  |  |  |
| --- | --- | --- | --- |
| Chemo-ADPT | Eribulin lines after A/MBC (excluding the first line) | | |
| Second line | Third line and above | *p* |
| Median (IQR) | 262.0 (64.0-581.0) | 182 (120.3-345.7) | 0.401 |
| Tertile distribution | n (%) | n (%) |  |
| 1st tertile (≤140.75 days) | 7 (33.3%) | 33 (34.0%) | 0.206 |
| 2nd tertile (>140.75 & ≤ 290.5 days) | 4 (19.1%) | 35 (36.1%) |  |
| 3rd tertile (>290.5 days) | 10 (47.6%) | 29 (29.9%) |  |

Chemo-ADPT= average duration of prior chemotherapy treatment lines before initiation of eribulin

A/MBC= recurrent advanced or metastatic breast cancer

IQR=interquartile range